Canadian researchers believe that a diet program involving FDA-recognized heart-healthy foods may be more effective at lowering LDL cholesterol than a low-saturated fat diet.
Canadian researchers believe that a diet program involving FDA-recognized heart-healthy foods may be more effective at lowering low-density lipoprotein (LDL) cholesterol than a low-saturated fat diet.
In a multi-center trial, the researchers assigned 351 hyperlipidemic adults to one of three dietary programs for six months: a control diet or an intervention diet containing heart-healthy food components, with dietician visits on two occasions (“routine”) or seven occasions (“intensive”). Changes in LDL cholesterol were measured over the course of the study.
The control diet emphasized low-fat dairy, whole grain cereals, fruits, vegetables, and avoidance of heart-healthy foods from the intervention diets.
Per 1000 kcal, the intervention diet aimed for 0.94 g of plant sterols, 9.8 g of viscous fibers (from oats, barley, and psyllium), 22.5 g of soy protein, and 22.5 g of nuts. Consumption of peas, beans, and lentil was encouraged.
“The specific food components used in the portfolio have well-established cholesterol-lowering properties and are recognized by the U.S. FDA as justifying a heart health claim,” wrote lead researcher David Jenkins, MD, of St. Michael’s Hospital (Toronto). “Review articles and meta-analyses have confirmed [LDL-cholesterol] benefits for viscous fibers, plant sterols, soy proteins, and nuts.”
By six months, participants in the control group had experienced a 3.0% decrease in LDL cholesterol. But participants in the intervention groups experienced significant reductions of 13.8% and 13.1% with the intensive and routine regimens, respectively.
With just two clinical visits and a food-specific dieting program, the researchers concluded that such a strategy might be suitable as a clinical approach.
Study limitations included a high drop-out rate of 22.6%, predominantly white participants, and participants who were considered to be at low to intermediate risk of cardiovascular disease. The effect of this type of dietary intervention on high-risk, obese subjects remains to be seen.
Funding and support for the study was provided by the Canada Research Chair Endowment of the Federal Government of Canada, the Canadian Institutes of Health Research, Advanced Foods and Materials Network (Guelph, ON), Loblaw Brands Ltd. (Brampton, ON), Solae (St. Louis, MO), and Unilever (Vlaardingen, the Netherlands, and Toronto, ON).
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.